Mephedrone ('bath salt') elicits conditioned place preference and dopamine-sensitive motor activation

Drug and Alcohol Dependence

Volumn 126, Issue 1-2, 2012, Pages 257-262

  Lisek, Renata ^a   Xu, Wei ^a   Yuvasheva, Ekaterina ^a   Chiu, Yi Ting ^a   Reitz, Allen B ^b   Liu Chen, Lee Yuan ^a   Rawls, Scott M ^a  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Fox Chase Chemical Diversity Center   (United States)

Author keywords

Bath salts; Conditioned place preference; Dopamine; Locomotor; Mephedrone; SCH 23390; Sulpiride

Indexed keywords

4' METHYLMETHCATHINONE; 8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; DOPAMINE; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; SULPIRIDE;

ANALYSIS OF VARIANCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG ABUSE; DRUG EXPOSURE; DRUG WITHDRAWAL; ENZYME ACTIVATION; MALE; MOBILIZATION; MOTOR ACTIVITY; MOUSE; NONHUMAN; PLACE PREFERENCE; PRIORITY JOURNAL; RAT;

ANIMALS; BENZAZEPINES; CENTRAL NERVOUS SYSTEM STIMULANTS; CONDITIONING, OPERANT; DOPAMINE; DOPAMINE ANTAGONISTS; MALE; METHAMPHETAMINE; MICE; MOTOR ACTIVITY; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, DOPAMINE D1; RECEPTORS, DOPAMINE D2; SULPIRIDE;

MUS; RATTUS;

EID: 84867893013     PISSN: 03768716     EISSN: 18790046     Source Type: Journal    
DOI: 10.1016/j.drugalcdep.2012.04.021     Document Type: Article

References (43)

1. Angoa-Pérez M., Kane M.J., Francescutti D.M., Sykes K.E., Shah M.M., Mohammed A.M., Thomas D.M., Kuhn D.M. Mephedrone, an abused psychoactive component of 'bath salts' and methamphetamine congener, does not cause neurotoxicity to dopamine nerve endings of the striatum. J. Neurochem. 2012, 120:1097-1107.
2. Al-Motarreb A., Al-Habori M., Broadley K.J. Khat chewing, cardiovascular diseases and other internal medical problems: the current situation and directions for future research. J. Ethnopharmacol. 2010, 132:540-548.
3. Ball K.T., Budreau D., Rebec G.V. Acute effects of 3,4-methylenedioxymethamphetamine on striatal single-unit activity and behavior in freely moving rats: differential involvement of dopamine D(1) and D(2) receptors. Brain Res. 2003, 994:203-215.
4. Ball K.T., Klein J.E., Plocinski J.A., Slack R. Behavioral sensitization to 3,4-methylenedioxymethamphetamine is long-lasting and modulated by the context of drug administration. Behav. Pharmacol. 2011, 22:847-850.
5. Baumann M.H., Ayestas M.A., Partilla J.S., Sink J.R., Shulgin A.T., Daley P.F., Brandt S.D., Rothman R.B., Ruoho A.E., Cozzi N.V. The designer methcathinone analogs, mephedrone and methylone, are substrates for monoamine transporters in brain tissue. Neuropsychopharmacology 2012, 37:1192-1203.
6. Bello E.P., Mateo Y., Gelman D.M., Noaín D., Shin J.H., Low M.J., Alvarez V.A., Lovinger D.M., Rubinstein M. Cocaine supersensitivity and enhanced motivation for reward in mice lacking dopamine D2 autoreceptors. Nat. Neurosci. 2011, 14:1033-1038.
7. Benoit-Marand M., Borrelli E., Gonon F. Inhibition of dopamine release via presynaptic D2 receptors: time course and functional characteristics in vivo. J. Neurosci. 2001, 21:9134-9141.
8. Benturquia N., Courtin C., Noble F., Marie-Claire C. Involvement of D1 dopamine receptor in MDMA-induced locomotor activity and striatal gene expression in mice. Brain Res. 2008, 1211:1-5.
9. Bilsky E.J., Reid L.D. MDL72222, a serotonin 5-HT3 receptor antagonist, blocks MDMA's ability to establish a conditioned place preference. Pharmacol. Biochem. Behav. 1991, 39:509-512.
10. Bubar M.J., Pack K.M., Frankel P.S., Cunningham K.A. Effects of dopamine D1- or D2-like receptor antagonists on the hypermotive and discriminative stimulus effects of (+)-MDMA. Psychopharmacology 2004, 173:326-336.
11. Cabib S., Castellano C., Cestari V., Filibeck U., Puglisi-Allegra S. D1 and D2 receptor antagonists differently affect cocaine-induced locomotor hyperactivity in the mouse. Psychopharmacology 1991, 105:335-339.
12. Carhart-Harris R.L., King L.A., Nutt D.J. A web-based survey on mephedrone. Drug Alcohol Depend. 2011, 118:19-22.
13. Cole J.C., Sumnall H.R. The pre-clinical behavioural pharmacology of 3,4-methylenedioxymethamphetamine (MDMA). Neurosci. Biobehav. Rev. 2003, 27:199-217.
14. Cragg S.J., Greenfield S.A. Differential autoreceptor control of somatodendritic and axon terminal dopamine release in substantia nigra, ventral tegmental area, and striatum. J. Neurosci. 1997, 17:5738-5746.
15. Cunningham C.L., Noble D. Methamphetamine-induced conditioned place preference or aversion depending on dose and presence of drug. Ann. N. Y. Acad. Sci. 1992, 654:431-433.
16. Degenhardt L., Bruno R., Topp L. Is ecstasy a drug of dependence?. Drug Alcohol Depend. 2010, 107:1-10.
17. Diller A.J., Rocha A., Cardon A.L., Valles R., Wellman P.J., Nation J.R. The effects of concurrent administration of +/-3,4-methylenedioxymethamphetamine and cocaine on conditioned place preference in the adult male rat. Pharmacol. Biochem. Behav. 2007, 88:165-170.
18. Garrett B.E., Holtzman S.G. D1 and D2 dopamine receptor antagonists block caffeine-induced stimulation of locomotor activity in rats. Pharmacol. Biochem. Behav. 1994, 47:89-94.
19. Gold L.H., Geyer M.A., Koob G.F. Neurochemical mechanisms involved in behavioral effects of amphetamines and related designer drugs. NIDA Res. Monogr. 1989, 94:101-126.
20. Hadlock G.C., Webb K.M., McFadden L.M., Chu P.W., Ellis J.D., Allen S.C., Andrenyak D.M., Vieira-Brock P.L., German C.L., Conrad K.M., Hoonakker A.J., Gibb J.W., Wilkins D.G., Hanson G.R., Fleckenstein A.E. 4-Methylmethcathinone(mephedrone): neuropharmacological effects of a designer stimulant of abuse. J. Pharmacol. Exp. Ther. 2011, 339:530-536.
21. Huang E.Y., Liu T.C., Tao P.L. Co-administration of dextromethorphan with morphine attenuates morphine rewarding effect and related dopamine releases at the nucleus accumbens. Naunyn Schmiedebergs Arch. Pharmacol. 2003, 368:386-392.
22. Jaworski J.N., Gonzales R.A., Randall P.K. Effect of dopamine D2/D3 receptor antagonist sulpiride on amphetamine-induced changes in striatal extracellular dopamine. Eur. J. Pharmacol. 2001, 418:201-206.
23. Kehr J., Ichinose F., Yoshitake S., Goiny M., Sievertsson T., Nyberg F., Yoshitake T. Mephedrone, compared to MDMA (ecstasy) and amphetamine, rapidly increases both dopamine and serotonin levels in nucleus accumbens of awake rats. Br. J. Pharmacol. 2011, 164:1949-1958.
24. Leri F., Franklin K.B. Effects of diazepam on conditioned place preference induced by morphine or amphetamine in the rat. Psychopharmacology 2000, 150:351-360.
25. Marona-Lewicka D., Rhee G.S., Sprague J.E., Nichols D.E. Reinforcing effects of certain serotonin-releasing amphetamine derivatives. Pharmacol. Biochem. Behav. 1996, 53:99-105.
26. Martínez-Clemente J., Escubedo E., Pubill D., Camarasa J. Interaction of mephedrone with dopamine and serotonin targets in rats. Eur. Neuropsychopharmacol. 2011, 22:231-236.
27. Meyer M.R., Maurer H.H. Metabolism of designer drugs of abuse: an updated review. Curr. Drug Metab. 2010, 11:468-482.
28. Motbey C.P., Hunt G.E., Bowen M.T., Artiss S., McGregor I.S. Mephedrone (4-methylmethcathinone, 'meow'): acute behavioural effects and distribution of Fos expression in adolescent rats. Addict. Biol. 2012, 17:409-422.
29. Newcombe R. Mephedrone: Use of Mephedrone (M-Cat, Meow) in Middlesbrough 2009, Lifeline Publications, Manchester, UK.
30. Pierce R.C., Bell K., Duffy P., Kalivas P.W. Repeated cocaine augments excitatory amino acid transmission in the nucleus accumbens only in rats having developed behavioral sensitization. J. Neurosci. 1996, 16:1550-1560.
31. Robinson T.E., Berridge K.C. The incentive sensitization theory of addiction: some current issues. Philos. Trans. R. Soc. Lond. B: Biol. Sci. 2008, 363:3137-3146.
32. Ross E.A., Watson M., Goldberger B. " Bath salts" intoxication. N. Engl. J. Med. 2011, 365:967-968.
33. Sanchis-Segura C., Spanagel R. Behavioural assessment of drug reinforcement and addictive features in rodents: an overview. Addict. Biol. 2006, 11:2-38.
34. Schifano F., Corkery J. Cocaine/crack cocaine consumption, treatment demand, seizures, related offences, prices, average purity levels and deaths in the UK (1990-2004). J. Psychopharmacol. 2008, 22:71-79.
35. Soderman A.R., Unterwald E.M. Cocaine-induced mu opioid receptor occupancy within the striatum is mediated by dopamine D2 receptors. Brain Res. 2009, 1296:63-71.
36. Steketee J.D., Kalivas P.W. Drug wanting: behavioral sensitization and relapse to drug-seeking behavior. Pharmacol. Rev. 2011, 63:348-365.
37. Stepens A., Logina I., Liguts V., Aldins P., Eksteina I., Platkājis A., Mārtinsone I., Trauds E., Rozentāle B., Donaghy M. A Parkinsonian syndrome in methcathinone users and the role of manganese. N. Engl. J. Med. 2008, 358:1009-1017.
38. Ushijima I., Carino M.A., Horita A. Involvement of D1 and D2 dopamine systems in the behavioral effects of cocaine in rats. Pharmacol. Biochem. Behav. 1995, 52:737-741.
39. Vanattou-Saïfoudine N., McNamara R., Harkin A. Caffeine promotes dopamine D1 receptor-mediated body temperature, heart rate and behavioural responses to MDMA ('ecstasy'). Psychopharmacology 2010, 211:15-25.
40. Vanderschuren L.J., Pierce R.C. Sensitization processes in drug addiction. Curr. Top. Behav. Neurosci. 2010, 3:179-195.
41. Vezina P., Stewart J. The effect of dopamine receptor blockade on the development of sensitization to the locomotor activating effects of amphetamine and morphine. Brain Res. 1989, 499:108-120.
42. Winstock A.R., Mitcheson L.R., Deluca P., Davey Z., Corazza O., Schifano F. Mephedrone, new kid for the chop?. Addiction 2011, 106:154-161.
43. Wood D.M., Davies S., Greene S.L., Button J., Holt D.W., Ramsey J., Dargan P.I. Case series of individuals with analytically confirmed acute mephedrone toxicity. Clin. Toxicol. 2010, 48:924-927.